机构：[1]Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114[2]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing China, 100730临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China[4]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430023, China华中科技大学同济医学院附属协和医院[5]Department of Chemical and Biological Engineering, Tufts University, Medford, MA 02155, USA[6]Neural Reconstructional Department, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China, 100050首都医科大学附属天坛医院
出处：
摘要：
Neurofibromatosis type 2 is characterized by bilateral vestibular schwannomas, which are benign tumors that originate from the nerve sheath and damage the nerve as they grow, causing neurological dysfunction such as hearing loss. Current standard radiation therapy can further augment hearing loss by inducing local damage to mature nerve tissue. Treatment with bevacizumab, a Vascular Endothelial Growth Factor (VEGF)-specific antibody, is associated with tumor control and hearing improvement in NF2 patients; however, its effect is not durable and its mechanism of action on improving nerve function is unknown. Anti-VEGF treatment can normalize the tumor vasculature, improving vessel perfusion and delivery of oxygen. It is known that oxygen is a potent radiosensitizer; therefore, combining anti-VEGF treatment with radiation therapy can achieve better tumor control and allow for the use of lower radiation doses, thus minimizing treatment-related neurological toxicity.
基金：
This study was supported by Department of Defense New Investigator Award (L.X.), American Cancer Society Research Scholar Award (L.X.), Ira Spiro Award (L.X.), NIH - P01CA080214, P50CA165962 and Outstanding Investigator Grant R35CA197743, and National Heart, Lung, And Blood Institute of the National Institutes of Health F31 Fellowship (F31HL126449, D.M.).
语种：
外文
PubmedID：
第一作者：
第一作者机构：[1]Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114[2]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing China, 100730
通讯作者：
通讯机构：[1]Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114[*1]Department of Radiation Oncology, Cox-7, Massachusetts General Hospital, Boston, Massachusetts 02114
推荐引用方式(GB/T 7714)：
Zhang Na,Gao Xing,Zhao Yingchao,et al.Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.[J].Journal of rare diseases research & treatment.2016,1(2):51-55.
APA：
Zhang Na,Gao Xing,Zhao Yingchao,Datta Meenal,Liu Pinan&Xu Lei.(2016).Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma..Journal of rare diseases research & treatment,1,(2)
MLA：
Zhang Na,et al."Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.".Journal of rare diseases research & treatment 1..2(2016):51-55
